| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/10/2001 | US6258774 Carrier for in vivo delivery of a therapeutic agent |
| 07/10/2001 | US6258385 Tetrasilver tetroxide treatment for skin conditions |
| 07/10/2001 | US6258378 Delivery of biologically active substance to target sites in the body of patients |
| 07/10/2001 | US6258377 Hydrophobic preparations containing medium chain monoglycerides |
| 07/10/2001 | US6258372 Xylitol nose spray |
| 07/10/2001 | US6258370 Applying optical brightener with intense fluorescence in ultraviolet radiation; monitoring skin; free of fluoroaliphatic surfactant and reducing agent |
| 07/10/2001 | US6258362 Genetically attenuated; vaccine contains polysaccharide and/or amino acid source, buffer, and monosaccharide, oligosaccharide, or sugar alcohol |
| 07/10/2001 | US6258358 Targeted immunostimulation with bispecific reagents |
| 07/10/2001 | US6258351 Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| 07/10/2001 | CA2076527C A process for the production of solid forms of active substances and the products obtained in this way |
| 07/10/2001 | CA2060666C Antigenic epitopes present on membrane-bound but not secreted iga |
| 07/05/2001 | WO2001048233A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | WO2001048231A2 Method of achieving persistent transgene expression |
| 07/05/2001 | WO2001048117A1 Dry compositions containing hydrophobic amino acid |
| 07/05/2001 | WO2001048091A1 Stabilizers for anthocyanin-rich compositions |
| 07/05/2001 | WO2001048052A1 Branched polyalkylene glycols |
| 07/05/2001 | WO2001048024A1 Stabilized cyclodextrin complexes |
| 07/05/2001 | WO2001047960A1 Uses of transport proteins for controlling cell cycle |
| 07/05/2001 | WO2001047911A1 Cationic amphiphiles, uses and synthesis method thereof |
| 07/05/2001 | WO2001047563A1 Use of lithium (li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 07/05/2001 | WO2001047562A2 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 07/05/2001 | WO2001047561A1 Hyaluronic acid in the treatment of cancer |
| 07/05/2001 | WO2001047560A2 Particulate vitamin composition |
| 07/05/2001 | WO2001047557A1 Oral preparations for diabetes |
| 07/05/2001 | WO2001047554A1 Stable antibody compositions and injection preparations |
| 07/05/2001 | WO2001047553A1 Micelle-forming lipopeptides targeted at antigen presenting cells useful as vaccine adjuvants |
| 07/05/2001 | WO2001047552A1 Polysialic acid-klh conjugate vaccine |
| 07/05/2001 | WO2001047549A2 Conjugate useful as building block for vaccine preparation |
| 07/05/2001 | WO2001047542A1 Vancomycin preparations |
| 07/05/2001 | WO2001047532A1 System for stabilizing lacrimal fluid layer |
| 07/05/2001 | WO2001047526A1 Remedies for external use for allergic skin diseases |
| 07/05/2001 | WO2001047525A1 Antipruritic agents for external use |
| 07/05/2001 | WO2001047521A1 Use of ketotifen as ophthalmic agent |
| 07/05/2001 | WO2001047519A1 Powdery biotin preparations |
| 07/05/2001 | WO2001047512A2 Method for relieving pain associated with an internal disease site |
| 07/05/2001 | WO2001047501A1 Drug delivery system exhibiting permeability control |
| 07/05/2001 | WO2001047500A1 Hydrogel-driven drug dosage form |
| 07/05/2001 | WO2001047499A1 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate |
| 07/05/2001 | WO2001047498A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 07/05/2001 | WO2001047497A2 Controlled release pharmaceutical composition containing tramadol hydrochloride |
| 07/05/2001 | WO2001047496A1 Histidine copolymer and methods for using same |
| 07/05/2001 | WO2001047495A1 Pharmaceutical compositions providing enhanced drug concentrations |
| 07/05/2001 | WO2001047493A1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 07/05/2001 | WO2001047492A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | WO2001047490A1 Devices for the delivery of drugs having antiprogestinic properties |
| 07/05/2001 | WO2001047420A1 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus |
| 07/05/2001 | WO2001047372A2 Absorbing fat chitosan |
| 07/05/2001 | WO2001040446A8 Pour-on formulations |
| 07/05/2001 | WO2001000654A3 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 07/05/2001 | WO2000078332A3 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/05/2001 | WO2000076464A3 Oxidatively stable, long-chain ethyl ester emollients |
| 07/05/2001 | WO2000074650A3 Implantable gel compositions and method of manufacture |
| 07/05/2001 | WO2000066138A3 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 07/05/2001 | WO2000050050A8 Multiparticulate formulation |
| 07/05/2001 | WO2000045850A3 Drug delivery vehicle |
| 07/05/2001 | WO2000023114A9 Polymer conjugates of interferon beta- 1a and their uses |
| 07/05/2001 | WO1999064045A9 Novel therapeutic agents for membrane transporters |
| 07/05/2001 | WO1999047135A8 Conjugated linoleic acid compositions |
| 07/05/2001 | US20010006989 Pre-polymerization, monomer(s) dissolved in water-miscible aprotic organic solvent forming non-solvent mixture of polymer; prophylactic or curative antibiotics or antiseptic agents |
| 07/05/2001 | US20010006968 Use of ophthalmic agent |
| 07/05/2001 | US20010006962 Behavior of biologically active compounds favorably modified by replacing a functional group with an unsaturated fatty derivative, e.g. elaidic acid; bioavailability; membrane passage; organ targeting; drugs; agriculture |
| 07/05/2001 | US20010006959 Displaying a beta-lactamase inhibitor protein on a virus, contacting the virus with a beta-lactamase binding protein target, selecting for the virus that has a higher affinity for the target and testing the beta-lactamase inhibitor protein |
| 07/05/2001 | US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity |
| 07/05/2001 | US20010006956 Maltitol crystals of particular forms, crystalline compositions containing them and processes for their preparation |
| 07/05/2001 | US20010006945 Hyperstructure-forming carriers |
| 07/05/2001 | US20010006817 Cell delivery compositions |
| 07/05/2001 | US20010006816 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses |
| 07/05/2001 | US20010006815 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses |
| 07/05/2001 | US20010006814 Chemical modification |
| 07/05/2001 | US20010006675 Forming a formulation comprising protease enzyme and polyvinyl alcohol film forming agent, topically applying the formulation, incubating to form a film incorporating enzyme, removing the film incorporating the enzyme from the site |
| 07/05/2001 | US20010006674 Mixture for use as wound dressing |
| 07/05/2001 | US20010006671 Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements |
| 07/05/2001 | US20010006667 Use and composition of an anti-sexually transmitted diseases formulation |
| 07/05/2001 | US20010006662 A lipid regulating agent selected from a fibrate or statin dispersed or dissolved in a hydrophilic, amorphous polymer in which antilipidimic agent present as metastable, amorphous phase |
| 07/05/2001 | US20010006652 Using oils selected from the group consisting of dialkyl ethers, dialkyl cyclohexanes, Guerbet alcohols, polyol polyhydroxystearates and/or hydroxycarboxylic acid esters |
| 07/05/2001 | US20010006650 Therapeutic agent dispersed in solid beadlet comprising at least 20% by weight of at least one hydrophobic long chain fatty acid or ester thereof and at least 3.0% by weight of at least one surfactant |
| 07/05/2001 | US20010006649 Stable oral pharmaceutical dosage forms |
| 07/05/2001 | US20010006645 Method for transdermal drug delivery |
| 07/05/2001 | US20010006640 Compounds and methods to inhibit or augment an inflammatory response |
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | US20010006634 Providing a bonding composition comprising isolated chondrocytes mixed with a biological gel, applying composition to a surface of first cartilage piece and contacting surface with second cartilage piece |
| 07/05/2001 | US20010006618 Intraoperative, intravascular and endoscopic tumor and lesion detection, biopsy and therapy |
| 07/05/2001 | US20010006616 Polymeric delivery of radionuclides and radiopharmaceuticals |
| 07/05/2001 | DE19963538A1 Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln Use of an enzyme to improve tissue resorption of drugs |
| 07/05/2001 | DE19960924A1 Amphiphile Polyamine, deren Anwendungen und Verfahren zu ihrer Synthese Amphiphilic polyamines, their applications and methods for their synthesis |
| 07/05/2001 | CA2396380A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | CA2395993A1 Antidiabetic preparation for oral administration |
| 07/05/2001 | CA2395575A1 Uses of transport proteins for controlling cell cycle |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395454A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | CA2394758A1 Histidine-containing copolymers enhance pharmaceutical agent delivery |
| 07/05/2001 | CA2394393A1 Remedies for external use for allergic skin diseases |
| 07/05/2001 | CA2363180A1 Use of lithium (li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 07/04/2001 | EP1113023A1 Method of forming agglomerates of polysaccharide with hydrophobic groups |
| 07/04/2001 | EP1113021A2 Polyamide-oligonucleotide derivatives, their production and use |
| 07/04/2001 | EP1112750A1 Drug composition for topical administration |
| 07/04/2001 | EP1112738A2 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 07/04/2001 | EP1112089A1 Compositions comprising sympathomimetic amine salts unsuitable for illegal use |
| 07/04/2001 | EP1112082A2 Stable liquid formulations of botulinum toxin |
| 07/04/2001 | EP1112075A1 Compositions for the treatment of male erectile dysfunction |